Unicharm (8113) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
8 May, 2026Executive summary
Q1 FY2026 consolidated sales rose 2.9% year-over-year to ¥234.2 billion, with core operating profit up 8.5% to ¥31.5 billion, reflecting benefits from structural reforms and offensive investments, though profit before tax fell 10.2% and profit attributable to owners dropped 20.7% due to lower other income and higher costs.
Overseas markets drove growth, offsetting a temporary contraction in Japan, where sales and profit declined due to cost-consciousness and shipment adjustments; steady market share was maintained in Japan and profitability improved in China.
Initiatives focused on sustainable growth, digital engagement, and product innovation across all segments.
The company maintained top market share and profitability in Japan, with a turnaround expected from Q2 as value-passing strategies take effect.
Financial highlights
Net sales: ¥234.2 billion (YoY +2.9%).
Core operating income: ¥31.5 billion (YoY +8.5%, margin 13.4%, +0.6pp).
Profit before tax: ¥31.4 billion (YoY -10.2%), impacted by absence of prior year insurance proceeds.
Profit attributable to owners: ¥19.8 billion (YoY -20.7%).
EBITDA: ¥43.3 billion (YoY -7.8%).
Basic EPS: ¥11.40 (YoY -19.6%).
Outlook and guidance
FY2026 sales forecast: ¥1,010 billion (+6.8% YoY); core operating profit: ¥136 billion (+24.9% YoY); net income attributable to owners projected to reach ¥86.5 billion (+32.6% YoY); basic EPS ¥50.26.
Dividend forecast for FY2026 raised to ¥22.00 per share (up from ¥18.00 in FY2025).
Q2 onward expected to see full-scale value-passing and recovery in Japan and Asia, with new product launches and continued aggressive investments.
Latest events from Unicharm
- Profits fell in FY2025, but FY2026 forecasts strong recovery and higher dividends.8113
Q4 202512 Feb 2026 - Sales and core profit declined, but profit attributable to owners rose 2.0% YoY.8113
Q3 20257 Nov 2025 - Sales and profits fell, but resilient regions and cost controls support a recovery outlook.8113
Q2 20255 Aug 2025 - Record sales and profit growth continue, with strong overseas and segment performance.8113
Q2 202413 Jun 2025 - Record sales and profit growth, with strong personal and pet care and rising dividends.8113
Q3 202413 Jun 2025 - Net profit jumped in Q1 FY2025 despite lower sales, aided by insurance proceeds.8113
Q1 20256 Jun 2025 - Record sales and profit growth, with a stock split and strong FY2025 outlook.8113
Q4 20245 Jun 2025